Calcitonin in the Treatment of Paget's Disease of Bone
Authors: C. CONRAD JOHNSTON
Journal: Annals of Internal Medicine (1972)

Editorial Notes1 April 1972Calcitonin in the Treatment of Paget's Disease of BoneC. CONRAD JOHNSTON JR., M.D., F.A.C.PC. CONRAD JOHNSTON JR., M.D., F.A.C.PSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-76-4-665_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIt has been estimated that one out of every 100 to 150 persons over 45 years of age has Paget's disease of bone and that 80% of affected individuals have symptoms (1). Skeletal pain is the most frequent clinical manifestation, but pathologic fractures, neurological symptoms, hearing loss, heart failure, and, rarely, osteogenic sarcoma also occur. Many forms of therapy have been used including corticoids, salicylates, sodium fluoride, and neutral phosphate, but none has proved entirely satisfactory, either because of lack of prolonged effectiveness or because of drug toxicity. The lesion is characterized by an acceleration of both bone resorption and...References1. HARRISKRANE ES: Paget's disease of bone. Bull Rheum Dis 18:506-511, 1968 Google Scholar2. HIRSCHMUNSON PP: Thyrocalcitonin. Physiol Rev 49:548-622, 1969 CrossrefMedlineGoogle Scholar3. BIJVOETVAN DER SLUYS VEERJANSEN OJA: Effects of calcitonin on patients with Paget's disease, thyrotoxicosis, or hypercalcaemia. Lancet 1:876-881, 1968 CrossrefMedlineGoogle Scholar4. BELLAVERYJOHNSTON NSC: Effects of calcitonin in Paget's disease and polystotic fibrous dysplasia. J Clin Endocrinol Metab 31:283-290, 1970 CrossrefMedlineGoogle Scholar5. HADDADBIRGEAVIOLO JSL: Effects of prolonged thyrocalcitonin administration on Paget's disease of bone. N Engl J Med 283:549-555, 1970 CrossrefMedlineGoogle Scholar6. SHAIBAKERWALLACH FRS: The clinical and metabolic effects of porcine calcitonin on Paget's disease of bone. J Clin Invest 50:1927-1940, 1971 CrossrefMedlineGoogle Scholar7. WOODHOUSEBORDIERFISHER NPM: Human calcitonin in the treatment of Paget's bone disease. Lancet 1:1139-1143, 1971 CrossrefMedlineGoogle Scholar8. DUBÉGOLDSMITHARNAUD WRS: Hyperparathyroidism secondary to long-term therapy of Paget's disease of bone with calcitonin (abstract). Clin Res 19:371, 1971 Google Scholar9. HANTMANDONALDSONHULLEY DCS: Abnormal urinary sediment during therapy with synthetic salmon calcitonin. J Clin Endocrinol Metab 33:564-566, 1971 CrossrefMedlineGoogle Scholar10. RYANSCHWARTZPERLIA WTC: Effects of mithramycin on Paget's disease of bone. Ann Intern Med 70:549-557, 1969 LinkGoogle Scholar11. SMITHRUSSELLBISHOP RRM: Diphosphonates and Paget's disease of bone. Lancet 1:945-947, 1971 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Department of Medicine Indiana University Medical Center Indianapolis, Ind. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByDrug Evaluation DataEffects of synthetic salmon calcitonin in patients with Paget's disease of boneInfluence of Disodium Etidronate on Clinical and Laboratory Manifestations of Paget's Disease of Bone (Osteitis Deformans) 1 April 1972Volume 76, Issue 4Page: 665-666KeywordsBoneCalcitoninHearingHeart failureLesionsNeurological drug therapyPhosphatesSalicylatesSarcomaSodium Issue Published: 1 April 1972 PDF DownloadLoading ...